Loading...
•
Sep 30, 2023
AbCellera Q3 2023 Earnings Report
AbCellera's revenue decreased significantly, and the company experienced a net loss in Q3 2023.
Key Takeaways
AbCellera reported a significant decrease in revenue to $6.6 million compared to $101.4 million in Q3 2022. The company had a net loss of $28.6 million, or $(0.10) per share, compared to net earnings of $26.6 million in Q3 2022. They reached a cumulative total of 110 partnered program starts and advanced one additional molecule into the clinic, bringing the cumulative total to ten molecules.
Total revenue was $6.6 million, a decrease from $101 million in Q3 2022.
Net loss was $28.6 million, compared to net earnings of $26.6 million in Q3 2022.
Cumulative partnered program starts reached 110.
Advanced one additional molecule into the clinic, bringing the cumulative total to ten molecules.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management.
Revenue & Expenses
Visualization of income flow from segment revenue to net income